May 15, 2020

Philips introduces new Philips Respironics E30 ventilator to help free up ICU units in wake of COVID-19

New emergency use ventilator with visual and audible alarms allows for high-flow oxygen to support COVID-19 patients with respiratory insufficiency, both invasively and non-invasively

Manila, Philippines – Royal Philips (NYSE: PHG, AEX: PHIA) recently announced its initiative to quickly scale production of its new Philips Respironics E30 ventilator as a readily available ventilation alternative during the COVID-19 crisis in situations where full-featured, critical care ventilators are not available. Philips will begin production immediately, ramping up outputs on an ongoing basis with expectations of producing 15,000 units per week in April 2020. This is expected to be available in the Philippines soon. This means that more patients can be treated by making this E30 available with a shorter lead time.

Designed for mass production by a team deeply experienced in respiratory care, the compact and cost effective E30 ventilator features include:

The ability to use the device both invasively and non-invasively;
It is easy to use. Quick set-up and simple operations, allowing healthcare providers with a wide range of skill sets to treat and monitor patients in clinical and field-hospital settings;
The ability to accept high-flow oxygen;
It is designed for safety. Recommended circuit set-ups contain a bacterial/viral filter to minimize exposure for healthcare providers when used invasively or noninvasively with example accessories that may be used, such as a full-face, non-vented (without integrated leak) mask, or helmet;
On-screen respiratory monitoring to measure and display vital ventilation type parameters such as pressure, tidal volume, respiratory rate, leak, and oxygen saturation, enabling clinicians to evaluate therapy effectiveness;
Visual and audible alarms to provide pertinent therapy information to healthcare providers.

“As COVID-19 continues to spread globally, healthcare providers are working diligently to treat soaring numbers of patients at a time when there are too few ventilators to provide care,” said Ashwin Chari, Country Manager, Philips Philippines. “Philips is responding to this pressing global need by quickly scaling production of the new Philips Respironics E30 ventilator with the needs of healthcare workers and COVID-19 patients in mind while also complying with medical device quality standards. Our hope is that this solution will help to free-up ICU ventilators for use in treating the most severe patients.”

The E30 is authorized for use by the US FDA under the Emergency Use Authorization (EUA) for ventilators, which authorizes its use for the duration of the US Health and Human Services COVID-19 public health emergency declaration justifying emergency use of these devices, unless terminated or revoked (after which the products may no longer be used). The Philippines FDA has cleared the E30 for import and use in the Philippines.

For more information on the Philips Respironics E30 ventilator, please click here.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Click here to read more Click here to read less